These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 10432959)

  • 1. [Treatment of postmenopausal osteoporosis with etidronate].
    Terranova R; Luca S
    Minerva Med; 1999 Mar; 90(3):85-90. PubMed ID: 10432959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease.
    Arase Y; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Ikeda K; Kumada H
    J Med Virol; 2008 Jul; 80(7):1302-7. PubMed ID: 18461628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.
    Storm T; Steiniche T; Thamsborg G; Melsen F
    J Bone Miner Res; 1993 Feb; 8(2):199-208. PubMed ID: 8442438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
    Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
    Nakamura T; Maekawa S; Morinobu S; Morinobu A; Koshiba M; Yamauchi M; Sugimoto T; Kumagai S
    Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
    Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
    J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
    Sato S; Ohosone Y; Suwa A; Yasuoka H; Nojima T; Fujii T; Kuwana M; Nakamura K; Mimori T; Hirakata M
    J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical drug appraisal: etidronate intermittent cyclic therapy for postmenopausal osteoporosis.
    Miller PD
    Br J Clin Pract; 1996; 50(1):23-31. PubMed ID: 8729598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Ros I; Alvarez L; Pons F; Caballería L; Monegal A; Martínez de Osaba MJ; Roca M; Peris P; Rodés J
    Am J Gastroenterol; 2003 Oct; 98(10):2268-74. PubMed ID: 14572578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
    Kushida K; Fukunaga M; Kishimoto H; Shiraki M; Itabashi A; Inoue T; Kaneda K; Morii H; Nawata H; Yamamoto K; Ohashi Y; Orimo H
    J Bone Miner Metab; 2004; 22(5):469-78. PubMed ID: 15316868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis.
    Thomas T; Lafage MH; Alexandre C
    J Rheumatol; 1995 Nov; 22(11):2183-5. PubMed ID: 8596168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
    Adachi JD; Roux C; Pitt PI; Cooper C; Moniz C; Dequeker J; Ioannidis G; Cawley MI; Jenkins EA; Walker-Bone KE; Pack S; Stephenson GF; Laan RF; Brown J; Geusens P
    J Rheumatol; 2000 Oct; 27(10):2424-31. PubMed ID: 11036840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.
    Morishige K; Yamamoto T; Sawada K; Ohmichi M; Tasaka K; Murata Y
    Arch Gynecol Obstet; 2003 Jun; 268(2):105-6. PubMed ID: 12768299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
    Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of oral biphosphonates in patients with cystic fibrosis and low bone mineral density].
    Ringuier B; Leboucher B; Leblanc M; Troussier F; Duveau E; Audran M; Giniès JL
    Arch Pediatr; 2004 Dec; 11(12):1445-9. PubMed ID: 15596332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis.
    Maugeri D; Mamazza C; Lo Giudice F; Puglisi N; Muscoso EG; Rizzotto M; Testaì M; Bennati E; Lentini A; Panebianco P
    Arch Gerontol Geriatr; 2005; 40(3):299-305. PubMed ID: 15814163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.